0 0
    • Mark all read All chats All chats
    Finabase
    • Categories
    • Register
    • Login
    • Watchlists
    • Portfolios
    • Map
    • Forex
    • Futures
    • Crypto
    • Comparisons
    • Alerts
    • Screeners
    • Backtests
    • vTrading
    • Settings
    1. Home
    2. BCRX
    • Alert
    • Note
    BCRX
    BioCryst Pharmaceuticals, Inc.
    5.69
    +
    0.02
    0.35%
    32 x 5.34
    11 x 6.06
    bid
    ask
    22 @ 04:00 PM
    5.82+0.13 (2.28%)
    Bearish 31
    Bullish 80
    sentiment
    5.60
    day range
    5.82
    4.83
    52 week range
    12.08
    04:00 PM
    V: 5.12M
    C: 5.69
    L: 5.60
    H: 5.82
    O: 5.65
    loading chart ...
    • 1d
    • 5d
    • 1m
    • 3m
    • 6m
    • ytd
    • 1y
    • 2y
    • 5y
    • max
    • PDF
    • Full Chart
    • Stats
    • Watchlist
    • Portfolio
    Prev Close5.67
    Open5.65
    Low5.60
    High5.82
    Volume5.12M
    Avg. Volume3.41M
    Market Cap1.17B
    Inst. Own93.70%
    Beta1.92
    Short Ratio7.71
    Div & Yield0.00 /
    EPS-1.25
    P/E0.00
    1yr Target14.09
    50day MA5.91
    200day MA7.35
    ^DJI
    Dow Jones Industrial Average
    36247.90
    04:55 PM
    +
    130.50
    0.36%
    ^IXIC
    NASDAQ Composite
    14404.00
    05:15 PM
    +
    64.00
    0.45%
    ^GSPC
    S&P 500
    4604.37
    04:55 PM
    +
    18.78
    0.41%
    AAPL
    194.78
    -0.93 (0.48%)
    Apple Inc.
    195.71
    22 @ 05:05 AM
    5 x 194.77
    1 x 194.86
    +
    1.44
    0.74%
    GOOG
    135.95
    -0.69 (0.50%)
    Alphabet Inc.
    136.64
    12 @ 05:05 AM
    14 x 0.00
    9 x 0.00
    -
    1.81
    1.31%
    AMZN
    146.40
    -1.02 (0.69%)
    Amazon.com, Inc.
    147.42
    11 @ 05:05 AM
    8 x 0.00
    14 x 0.00
    +
    0.54
    0.37%
    MSFT
    373.19
    +0.15 (0.04%)
    Microsoft Corporation
    373.04
    5 @ 05:05 AM
    8 x 0.00
    11 x 0.00
    +
    2.09
    0.56%
    BABA
    70.80
    -1.34 (1.86%)
    Alibaba Group Holding Limited
    72.14
    14 @ 05:06 AM
    13 x 0.00
    14 x 70.77
    -
    0.19
    0.26%
    NFLX
    454.54
    +0.78 (0.17%)
    Netflix, Inc.
    453.76
    15 @ 05:05 AM
    1 x 453.01
    1 x 455.20
    +
    1.76
    0.39%
    TSLA
    242.60
    -1.24 (0.51%)
    Tesla, Inc.
    243.84
    3 @ 05:06 AM
    1 x 242.47
    1 x 242.58
    +
    1.20
    0.49%
    NVDA
    474.55
    -0.51 (0.11%)
    NVIDIA Corporation
    475.06
    10 @ 05:05 AM
    1 x 474.40
    43 x 474.55
    +
    9.10
    1.95%
    AMD
    129.65
    +0.73 (0.57%)
    Advanced Micro Devices, Inc.
    128.92
    11 @ 05:05 AM
    9 x 0.00
    12 x 129.76
    +
    0.55
    0.43%
    MU
    74.99
    +0.03 (0.04%)
    Micron Technology, Inc.
    74.96
    16 @ 05:06 AM
    1 x 74.99
    1 x 75.34
    +
    1.31
    1.78%
    SPY
    460.09
    -0.11 (0.02%)
    SPDR S&P 500 ETF Trust
    460.20
    13 @ 05:06 AM
    1 x 460.01
    11 x 460.08
    +
    1.97
    0.43%
    TQQQ
    44.68
    -0.15 (0.33%)
    ProShares UltraPro QQQ
    44.83
    10 @ 05:06 AM
    7 x 44.67
    29 x 44.68
    +
    0.53
    1.20%
    BRK-A
    538700.00
    -1300.00 (0.24%)
    Berkshire Hathaway Inc.
    540000.00
    9 @ 04:00 PM
    9 x 0.00
    9 x 0.00
    +
    2220.00
    0.41%
    Day Gain
    Gain
    Market Val
    Costs
    Cash
    Portfolio
    Realized
    Dividend
    • Summary
    • Discussion
    • News
    • Signals
    • Financials
    • Alerts
    • Notes
    • Chart
    • Backtest
    News ...
    Is BioCryst Pharmaceuticals Inc (BCRX) Stock a Bad Value Thursday? news.google.com •
    JP Morgan lifts Biocryst Pharmaceuticals Inc. [BCRX] price estimate. Who else is bullish? – The DBT News news.google.com •
    BioCryst Pharmaceuticals Inc (BCRX) is up 3.31% in a Week, Should You Accumulate? news.google.com •
    BioCryst to Present at Upcoming Investor Conferences globenewswire.com •
    BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology globenewswire.com •
    BioCryst to Report Third Quarter 2023 Financial Results on November 2 globenewswire.com •
    Profile ...
    BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
    Earning ...
    Date For Estimate Reported Surprise surprise %
    2023-11-02 2023-09 -0.25 -0.19 0.06 24.00%
    2023-08-03 2023-06 -0.25 -0.24 0.01 4.00%
    2023-05-03 2023-03 -0.3 -0.28 0.02 6.67%
    2023-02-21 2022-12 -0.19 -0.38 -0.19 -100.00%
    2022-11-01 2022-09 -0.32 -0.23 0.09 28.13%
    2022-08-04 2022-06 -0.36 -0.32 0.04 11.11%
    Upgrade / Downgrade ...
    Date Firm Action From To
    2023-09-24 RBC Capital Upgrade Outperform Outperform
    2023-09-17 RBC Capital Upgrade Sector Perform Outperform
    2023-08-03 RBC Capital Upgrade Sector Perform Sector Perform
    2023-08-03 Jefferies Upgrade Hold Buy
    2023-08-03 HC Wainwright & Co. Upgrade Buy Buy
    2023-08-02 Needham Upgrade Buy
    Insider Holder ...
    Date Name Relation Quantity Description
    2023-06-12 ABERCROMBIE GEORGE B Director 29.61K Stock Award(Grant)
    2023-06-12 ASELAGE STEPHEN J Director 63.34K Stock Award(Grant)
    2023-06-12 GALSON STEVEN K Director 29.61K Stock Award(Grant)
    2023-11-29 HEGGIE THERESA Director 50.86K Stock Award(Grant)
    2023-06-13 HUTSON NANCY J Director 81.82K Sale
    2023-06-12 LEE KENNETH B. Director 68.86K Stock Award(Grant)
    Institution Ownership ...
    Report Date Organization Position Value Percentage
    2023-06-29 Blackrock Inc. 15.50M 109.09M 8.18%
    2023-06-29 Vanguard Group Inc 15.09M 106.23M 7.96%
    2023-06-29 Baker Brothers Advisors, LLC 12.71M 89.48M 6.71%
    2023-06-29 State Street Corporation 12.26M 86.34M 6.47%
    2023-06-29 Avoro Capital Advisors LLC 12.06M 84.87M 6.36%
    2023-06-29 Assenagon Asset Management S.A. 5.33M 37.54M 2.81%
    Fund Ownership ...
    Report Date Organization Position Value Percentage
    2023-08-30 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 8.22M 58.41M 4.34%
    2023-06-29 Vanguard Total Stock Market Index Fund 5.86M 41.26M 3.09%
    2023-08-30 iShares Russell 2000 ETF 4.29M 30.51M 2.26%
    2023-08-30 Fidelity Select Portfolios - Biotechnology 2.81M 19.96M 1.48%
    2023-06-29 Vanguard Extended Market Index Fund 2.58M 18.14M 1.36%
    2023-06-29 Vanguard Small-Cap Index Fund 2.44M 17.17M 1.29%
    Dividend ...
    Dividend Date
    0 2014-06-11
    0 2014-06-05
    0 2014-05-20
    0 2014-05-16
    0 2014-04-02
      • Oldest to Newest
      • Newest to Oldest
      • Most Votes
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 20
    • 21
    • 4 / 21
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 22 - last edited by
      #61

      $BCRX @Harrington with all the trash you spout this is about as far as your going to get buddy

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 21 - last edited by
      #62

      $BCRX I think it’s time

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 21 - last edited by
      #63

      $BCRX BASTARDS BASTARDS BASTARDS……….

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 21 - last edited by
      #64

      $BCRX So much for that 1k share add at “this is going to be the bottom” price of 9.97.

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 21 - last edited by
      #65

      $BCRX You ever felt like you’ve been stabbed in the back…just wondering?

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 21 - last edited by
      #66

      $BCRX @Spencer I did the same thing, a lot of hopes and dreams dashed.

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 18 - last edited by
      #67

      $BCRX May help control the bleeding…sorry

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 18 - last edited by
      #68

      $BCRX @experiment 626 You might have Menorrhagia you might try Neproxen it may help go try the bleeding

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 17 - last edited by
      #69

      $BCRX @William @Louie Thank you both should be mandatory reading.

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 8 - last edited by
      #70

      $BCRX Come on they temporarily halted enrollment of new individuals but continue to treat existing patients. Like @Noa said use your noggin for something other than a hat rack

      1 Reply Last reply
      0
    • S Offline
      S Offline
      sean.codier | Only
      wrote on Apr 8 - last edited by
      #71

      So the trial wasn’t halted…

      This is an important distinction. Enrollment was halted.

      Anybody going to be surprised if they come back a week or two from now and say “yeah, it’s fine, continue enrollment”. And then Pfizer rolls in with an offer, but already has 20M shares somehow?

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Apr 8 - last edited by
      #72

      $BCRX 4.28 avg. on 20k but it hurts like hell

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 22 - last edited by
      #73

      $BCRX We we’re on edge 13 hrs ago

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 21 - last edited by
      #74

      $BCRX What the hell was all of that about?

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 20 - last edited by
      #75

      $BCRX Did someone call for a Rabbit

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 16 - last edited by
      #76

      $BCRX Alright I don’t want to play any more let’s get back to business

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 15 - last edited by
      #77

      $BCRX Come on man did @Ron Harrington/The Painted Sea Turd leak another one of his top secret CONCERNS

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 13 - last edited by
      #78

      $BCRX @Ryan I’m concerned that @Ron Harrington may take offense to your post …Oh No!

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 10 - last edited by
      #79

      $BCRX OUCH !

      1 Reply Last reply
      0
    • oriley.servicesO Offline
      oriley.servicesO Offline
      oriley.services | Only
      wrote on Mar 9 - last edited by
      #80

      $BCRX I’m 76 yrs old not in good health war raging on threats of a nuclear attack and I sit here with a smile on my face watching OUR BEAUTIFUL $BCRX do it’s thing We are blessed.

      1 Reply Last reply
      0
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 20
    • 21
    • 4 / 21
    • Is BioCryst Pharmaceuticals Inc (BCRX) Stock a Bad Value Thursday?
      news.google.com •

    • JP Morgan lifts Biocryst Pharmaceuticals Inc. [BCRX] price estimate. Who else is bullish? – The DBT News
      news.google.com •

    • BioCryst Pharmaceuticals Inc (BCRX) is up 3.31% in a Week, Should You Accumulate?
      news.google.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
      globenewswire.com •

    • BioCryst to Report Third Quarter 2023 Financial Results on November 2
      globenewswire.com •

    • BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains?
      zacks.com •

    • BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
      proactiveinvestors.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
      seekingalpha.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
      zacks.com •

    • BioCryst to Report Second Quarter 2023 Financial Results on August 3
      globenewswire.com •

    • BioCryst to Present at Upcoming Investor Conference
      globenewswire.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Stock Is Soaring Today
      fool.com •

    • BioCryst to Report First Quarter 2023 Financial Results on May 3
      globenewswire.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst: Good Candidate For Buyout, But Not For Anything Else
      seekingalpha.com •

    • Why Shares of BioCryst Pharmaceuticals Jumped Today
      fool.com •

    • BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
      seekingalpha.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
      seekingalpha.com •

    • Why BioCryst Pharmaceuticals Stock Is Sinking Today
      fool.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
      zacks.com •

    • Why Earnings Season Could Be Great for BioCryst (BCRX)
      zacks.com •

    • BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
      globenewswire.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
      globenewswire.com •

    • Pharmaceutical Stock Sinks on Sales Forecast
      schaeffersresearch.com •

    • BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
      globenewswire.com •

    • BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
      seekingalpha.com •

    • BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
      zacks.com •

    • BCRX Stock Sinks as BioCryst Discontinues Drug Development
      investorplace.com •

    • BioCryst to discontinue development of drug
      marketwatch.com •

    • BioCryst to Present at JMP Securities Hematology & Oncology Summit
      globenewswire.com •

    • 3 Biotechnology stocks under 10 dollars to buy now
      thedogofwallstreet.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
      seekingalpha.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
      zacks.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
      globenewswire.com •

    • CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
      investors.com •

    • BioCryst to Report Third Quarter 2022 Financial Results on November 1
      globenewswire.com •

    • Got $3,000? Here Are 2 Stocks That Will Make You Richer
      fool.com •

    • 3 Biotech Stocks to Buy Now for Extraordinary Gains
      investorplace.com •

    • Options Bulls Blast Phama Stock on Lifted Clinical Hold
      schaeffersresearch.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 Results - Earnings Call Transcript
      seekingalpha.com •

    • Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
      fool.com •

    • 3 Fast-Growing Stocks to Buy Now
      fool.com •

    • BioCryst to Report Second Quarter 2022 Financial Results on August 4
      globenewswire.com •

    • BioCryst to Present at Upcoming Investor Conference
      globenewswire.com •

    • BioCryst: A Prudent Diversification
      seekingalpha.com •

    • Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength?
      zacks.com •

    • Why BioCryst Pharmaceuticals Topped the Market Today
      fool.com •

    • 7 Cheap Biotech Stocks to Buy Now
      investorplace.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • Why BioCryst Stock Lost Nearly 4% of Its Value Today
      fool.com •

    • Why BioCryst Stock Shot Nearly 5% Higher Today
      fool.com •

    • BioCryst to Report First Quarter 2022 Financial Results on May 5
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Stock Sank Today
      fool.com •

    • Why BioChryst Pharmaceuticals' Stock Jumped 14.7% This Week
      fool.com •

    • Strength Seen in BioCryst (BCRX): Can Its 15.2% Jump Turn into More Strength?
      zacks.com •

    • BioCryst (BCRX) Pauses Enrolment in Key Studies, Stock Down
      zacks.com •

    • Why BioCryst Pharmaceuticals Stock Is Falling
      benzinga.com •

    • BioCryst to Present at Upcoming Investor Conference
      globenewswire.com •

    • Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder
      benzinga.com •

    • Why BioCryst Pharmaceuticals Stock Is Plunging Today
      benzinga.com •

    • Why BioCryst Pharmaceuticals Stock Slid Today
      fool.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
      zacks.com •

    • Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts?
      benzinga.com •

    • Updated Guidance And Royalty Pharma Financing Demolish Short Thesis For BioCryst Pharmaceuticals
      seekingalpha.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Stock Is Skyrocketing This Week
      fool.com •

    • BioCryst Pharmaceuticals Stock (BCRX): Why The Price Surged Today
      pulse2.com •

    • Why BioCryst Pharmaceuticals Stock Is Jumping on Monday
      fool.com •

    • BioCryst Provides Tremendous Option Value
      seekingalpha.com •

    • BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
      seekingalpha.com •

    • BioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930
      zacks.com •

    • BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
      benzinga.com •

    • 7 Top Growth Stocks to Buy as We Step Into November
      investorplace.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • Here's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
      fool.com •

    • BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
      globenewswire.com •

    • BioCryst to Report Third Quarter 2021 Financial Results on November 3
      globenewswire.com •

    • 7 Best Growth Stocks to Buy and Hold for the Next 10 Years
      investorplace.com •

    • 2 Super-Charged Growth Stocks to Buy Now
      fool.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • 3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
      fool.com •

    • NICE Recommends BioCryst's Hereditary Angioedema Med
      benzinga.com •

    • NICE Recommends BioCryst's ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
      globenewswire.com •

    • What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
      seekingalpha.com •

    • BioCryst to Present at Upcoming Investor Conferences
      globenewswire.com •

    • BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      globenewswire.com •

    • US Government Exercises Option To Buy Additional Doses Of BioCryst's Flu Med
      benzinga.com •

    • U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile
      globenewswire.com •

    • BioCryst Appoints Dr. Steven Galson to Board of Directors
      globenewswire.com •

    • BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Canada and Swissmedic
      globenewswire.com •

    • 2 Soaring Biotech Stocks With More Fuel in the Tank
      fool.com •

    • BioCryst Stock Jumps After Pulling Out $200M Equity Raise
      benzinga.com •

    • BioCryst Withdraws Public Offering
      globenewswire.com •

    • Why BioCryst Pharmaceuticals Rose 8% on Thursday
      fool.com •

    • BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q2 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • First post
      Last post
    0
    • Categories
    • Login

    • Don't have an account? Register

    • Login or register to search.
    Copyright © 2023 finabase.io